TY - JOUR
T1 - Supportive care in pediatric acute myeloid leukemia
T2 - Expert-based recommendations of the NOPHO-DB-SHIP consortium
AU - Arad-Cohen, Nira
AU - Zeller, Bernward
AU - Abrahamsson, Jonas
AU - Fernandez Navarro, Jose Maria
AU - Cheuk, Daniel
AU - Palmu, Sauli
AU - Costa, Vitor
AU - De Moerloose, Barbara
AU - Hasle, Henrik
AU - Jahnukainen, Kirsi
AU - Pronk, Cornelis Jan
AU - Gísli Jónsson, Ólafur
AU - Kovalova, Zhanna
AU - Lausen, Birgitte
AU - Munthe-Kaas, Monica
AU - Noren-Nyström, Ulrika
AU - Palle, Josefine
AU - Pasauliene, Ramune
AU - Saks, Kadri
AU - Kaspers, Gertjan Jl
PY - 2022/11
Y1 - 2022/11
N2 - INTRODUCTION: Pediatric acute myeloid leukemia (AML) is the second most common type of pediatric leukemia. Patients with AML are at high risk for several complications such as infections, typhlitis, and acute and long-term cardiotoxicity. Despite this knowledge, there are no definite supportive care guidelines as to what the best approach is to manage or prevent these complications.AREA COVERED: The NOPHO-DB-SHIP (Nordic-Dutch-Belgian-Spain-Hong-Kong-Israel-Portugal) consortium, in preparation for a new trial in pediatric AML patients, had dedicated meetings for supportive care. In this review, the authors discuss the available data and outline recommendations for the management of children and adolescents with AML with an emphasis on hyperleukocytosis, tumor lysis syndrome, coagulation abnormalities and bleeding, infection, typhlitis, malnutrition, cardiotoxicity, and fertility preservation.EXPERT OPINION: Improved supportive care has significantly contributed to increased cure rates. Recommendations on supportive care are an essential part of treatment for this highly susceptible population and will further improve their outcome.
AB - INTRODUCTION: Pediatric acute myeloid leukemia (AML) is the second most common type of pediatric leukemia. Patients with AML are at high risk for several complications such as infections, typhlitis, and acute and long-term cardiotoxicity. Despite this knowledge, there are no definite supportive care guidelines as to what the best approach is to manage or prevent these complications.AREA COVERED: The NOPHO-DB-SHIP (Nordic-Dutch-Belgian-Spain-Hong-Kong-Israel-Portugal) consortium, in preparation for a new trial in pediatric AML patients, had dedicated meetings for supportive care. In this review, the authors discuss the available data and outline recommendations for the management of children and adolescents with AML with an emphasis on hyperleukocytosis, tumor lysis syndrome, coagulation abnormalities and bleeding, infection, typhlitis, malnutrition, cardiotoxicity, and fertility preservation.EXPERT OPINION: Improved supportive care has significantly contributed to increased cure rates. Recommendations on supportive care are an essential part of treatment for this highly susceptible population and will further improve their outcome.
KW - Adolescent
KW - Child
KW - Humans
KW - Leukemia, Myeloid, Acute/therapy
KW - Typhlitis
KW - Cardiotoxicity
U2 - 10.1080/14737140.2022.2131544
DO - 10.1080/14737140.2022.2131544
M3 - Review Article
C2 - 36191604
SN - 1473-7140
VL - 22
SP - 1183
EP - 1196
JO - EXPERT REVIEW OF ANTICANCER THERAPY
JF - EXPERT REVIEW OF ANTICANCER THERAPY
IS - 11
ER -
